<?xml version="1.0" encoding="UTF-8"?>
<p>Atomoxetine, a noradrenergic reuptake inhibitor, and clozapine, an inhibitor of serotonin and dopamine receptors, as well as second-generation tricyclic antidepressant (TCA) nortriptyline and pramipexole, have been shown to be beneficial for the regulation of attention, psychosis, and depression, respectively, by evidence from several placebo-controlled trials [
 <xref rid="B93" ref-type="bibr">93</xref>, 
 <xref rid="B106" ref-type="bibr">106</xref>, 
 <xref rid="B107" ref-type="bibr">107</xref>].
</p>
